Literature DB >> 28658958

Collagen affinity coating for surface binding of decorin and other biomolecules: Surface characterization.

Marisa L Sylvester1, Buddy D Ratner1.   

Abstract

The development of biomaterials that promote tissue reconstruction and regeneration can reduce the low level, chronic inflammation and encapsulation that impact the performance of today's medical devices. Specifically, in the case of implantable sensors, the host response often leads to poor device performance that discourages permanent implantation. Our goal is to present on medical implants bioactive molecules that can promote healing rather than scarring. Localized delivery of these molecules would also minimize the possibility of adverse tissue reactions elsewhere in the body. Toward this end, the authors have developed a collagen affinity coating that binds a number of potential healing molecules and can be attached to the surface of an implanted biomaterial. This allows the creation of a wide variety of natural surface coatings that can be evaluated and tailored to promote the desired healing response. To demonstrate the efficacy of this collagen affinity coating to biospecifically bind promising healing molecules to type I collagen in vivo, the antifibrotic proteoglycan decorin was utilized. Decorin binds and renders ineffective the protein transforming growth factor beta (TGFβ) that induces collagen scar production. Thus, an assembled, supramolecular structure of biomaterial-collagen-decorin-TGFβ is formed. A decorin surface coating was created and characterized, illustrating the potential of this type I collagen affinity coating for widespread use with a variety of promising healing molecules. Future studies will test the implant efficacy of this type of coating.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28658958      PMCID: PMC5489414          DOI: 10.1116/1.4989835

Source DB:  PubMed          Journal:  Biointerphases        ISSN: 1559-4106            Impact factor:   2.456


  25 in total

1.  Decorin binds near the C terminus of type I collagen.

Authors:  D R Keene; J D San Antonio; R Mayne; D J McQuillan; G Sarris; S A Santoro; R V Iozzo
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

2.  Collagen-binding peptidoglycans: a biomimetic approach to modulate collagen fibrillogenesis for tissue engineering applications.

Authors:  John E Paderi; Rizaldi Sistiabudi; Albena Ivanisevic; Alyssa Panitch
Journal:  Tissue Eng Part A       Date:  2009-10       Impact factor: 3.845

3.  A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen-mediated platelet aggregation.

Authors:  T M Chiang; A H Kang
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats.

Authors:  J W Fischer; M G Kinsella; M M Clowes; S Lara; A W Clowes; T N Wight
Journal:  Circ Res       Date:  2000-03-31       Impact factor: 17.367

5.  Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.

Authors:  A Hildebrand; M Romarís; L M Rasmussen; D Heinegård; D R Twardzik; W A Border; E Ruoslahti
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

6.  Collagen I and III and their decorin modified surfaces studied by atomic force microscopy and the elucidation of their affinity toward positive apolipoprotein B-100 residue by quartz crystal microbalance.

Authors:  Joanna Witos; Julien Saint-Guirons; Kristoffer Meinander; Lucia D'Ulivo; Marja-Liisa Riekkola
Journal:  Analyst       Date:  2011-07-26       Impact factor: 4.616

7.  Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty.

Authors:  Nafiseh Nili; Asim N Cheema; Frank J Giordano; Alan W Barolet; Saeid Babaei; Reed Hickey; Mohammad R Eskandarian; Mirjam Smeets; Jagdish Butany; Gerard Pasterkamp; Bradley H Strauss
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Authors:  W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

9.  Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.

Authors:  Y Isaka; D K Brees; K Ikegaya; Y Kaneda; E Imai; N A Noble; W A Border
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

10.  Binding of fibromodulin and decorin to separate sites on fibrillar collagens.

Authors:  E Hedbom; D Heinegård
Journal:  J Biol Chem       Date:  1993-12-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.